Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SHBG | P04278 | 1/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.34 |
| ▸ | CA12 | O43570 | 2/20 | 0.34 |
| ▸ | CA1 | P00915 | 2/20 | 0.34 |
| ▸ | CA2 | P00918 | 2/20 | 0.34 |
| ▸ | MMP2 | P08253 | 2/20 | 0.34 |
| ▸ | CA9 | Q16790 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | ADH1B | P00325 | 1/20 | 0.31 |
| ▸ | ADH1C | P00326 | 1/20 | 0.31 |
| ▸ | ADH1A | P07327 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16590946 | 0.87 | SHBG (0.42) | SHBGEPHX1CA12CA1CA2 | |
| SCHEMBL24722747 | 0.84 | SHBG (0.38) | SHBGEPHX1CA12CA1CA2 | |
| SCHEMBL10437743 | 0.84 | SHBG (0.43) | SHBGEPHX1CA12CA1CA2 | |
| SCHEMBL3313525 | 0.84 | SHBG (0.43) | SHBGEPHX1CA12CA1CA2 | |
| SCHEMBL3311552 | 0.81 | SHBG (0.39) | SHBGEPHX1CA12CA1CA2 | |
| SCHEMBL8160857 | 0.75 | SHBG (0.33) | SHBG | |
| SCHEMBL2831266 | 0.75 | SHBG (0.37) | SHBGEPHX1CA12CA1CA2 | |
| SCHEMBL17789938 | 0.75 | SHBG (0.37) | SHBGEPHX1CA12CA1CA2 | |
| SCHEMBL20594356 | 0.73 | SHBG (0.43) | SHBGEPHX1CA12CA1CA2 | |
| SCHEMBL20594181 | 0.73 | SHBG (0.43) | SHBGEPHX1CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1934215-A1 | ISOTOPICALLY SUBSTITUTED IMIDAZOPYRIDINE DERIVATIVES FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS | Nycomed GmbH (DE) | 2008-06-25 | — | — | EP | disclosed |
| EP-1926714-A1 | ISOTOPICALLY SUBSTITUTED BENZIMIDAZOLE DERIVATIVES | Nycomed GmbH (DE) | 2008-06-04 | — | — | EP | disclosed |
| US-20080119510-A1 | Substituted Imidazo [4,5-B] Pyridines As Inhibitors Of Gastric Acid Secretion | ALTANA PHARMA AG (DE) | 2008-05-22 | — | — | US | disclosed |
| EP-1910313-A1 | 6-THIOAMIDE SUBSTITUTED BENZIMIDAZOLES | Nycomed GmbH (DE) | 2008-04-16 | — | — | EP | disclosed |
| WO-2008015196-A1 | 5-,7-BIS-SUBSTITUTED IMIDAZO[1,2-A]PYRIDINES | NYCOMED GMBH (DE) | 2008-02-07 | — | — | WO | disclosed |
| US-7326718-B2 | 8-Substituted imidazopyridines | ALTANA PHARMA AG (DE) | 2008-02-05 | — | — | US | disclosed |
| EP-1824850-A2 | SUBSTITUTED IMIDAZO[4,5-b]PYRIDINES AS INHIBITORS OF GASTRIC ACID SECRETION | Nycomed GmbH (DE) | 2007-08-29 | — | — | EP | disclosed |
| WO-2007039464-A1 | ISOTOPICALLY SUBSTITUTED IMIDAZOPYRIDINE DERIVATIVES FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS | NYCOMED GMBH (DE) | 2007-04-12 | — | — | WO | disclosed |
| WO-2007023135-A1 | ISOTOPICALLY SUBSTITUTED BENZIMIDAZOLE DERIVATIVES | NYCOMED GMBH (DE) | 2007-03-01 | — | — | WO | disclosed |
| EP-1756067-A1 | 7-SUBSTITUTED BENZIMIDAZOLES AND THEIR USE AS INHIBITORS OF GASTRIC ACID SECRETION | Altana Pharma AG (DE) | 2007-02-28 | — | — | EP | disclosed |
| US-20040214852-A1 | Polysubstituted imidazopyridines | ALTANA PHARMA AG (DE) | 2004-10-28 | — | — | US | disclosed |
| WO-2004046144-A1 | 8-SUBSTITUTED IMIDAZOPYRIDINES | ALTANA PHARMA AG (DE) | 2004-06-03 | — | — | WO | disclosed |
| US-20040106642-A1 | POLYSUBSTITUTED IMIDAZOPYRIDINES AS GASTRIC SECRETION INHIBITORS | ALTANA PHARMA AG (DE) | 2004-06-03 | — | — | US | disclosed |
| EP-1419156-A1 | ALKYL-SUBSTITUTED IMIDAZOPYRIDINES FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS | ALTANA Pharma AG (DE) | 2004-05-19 | — | — | EP | disclosed |
| EP-1417208-A1 | AMINO-SUBSTITUTED IMIDAZOPYRIDINES FOR THE TREATMENT OF GASTROINTESTINAL DISEASES | ALTANA Pharma AG (DE) | 2004-05-12 | — | — | EP | disclosed |
| WO-2003091253-A1 | NITROSATED IMIDAZOPYRIDINES | ALTANA PHARMA AG (DE) | 2003-11-06 | — | — | WO | disclosed |
| EP-1332143-A1 | POLYSUBSTITUTED IMIDAZOPYRIDINES AS GASTRIC SECRETION INHIBITORS | ALTANA Pharma AG (DE) | 2003-08-06 | — | — | EP | disclosed |
| WO-2003016310-A1 | ALKYL-SUBSTITUTED IMIDAZOPYRIDINES FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS | ALTANA PHARMA AG (DE) | 2003-02-27 | — | — | WO | disclosed |
| WO-2003014120-A1 | AMINO-SUBSTITUTED IMIDAZOPYRIDINES FOR THE TREATMENT OF GASTROINTESTINAL DISEASES | ALTANA PHARMA AG (DE) | 2003-02-20 | — | — | WO | disclosed |
| WO-2002034749-A1 | POLYSUBSTITUTED IMIDAZOPYRIDINES AS GASTRIC SECRETION INHIBITORS | ALTANA PHARMA AG (DE) | 2002-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106642-A1 | POLYSUBSTITUTED IMIDAZOPYRIDINES AS GASTRIC SECRETION INHIBITORS | GIPR, SLC10A2, VIP | SHBG 2692/4885EPHX1 3478/4885CA12 2639/4885 |
| US-20080119510-A1 | Substituted Imidazo [4,5-B] Pyridines As Inhibitors Of Gastric Acid Secretion | GIPR, CCKBR, GRPR | SHBG 3312/4885EPHX1 1363/4885CA12 1097/4885 |
| US-20040214852-A1 | Polysubstituted imidazopyridines | GIPR, VIP, SLC10A2 | SHBG 2441/4885EPHX1 3587/4885CA12 2601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.